Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
Emend jest lekiem przeciwwymiotnym, zapobiegającym nudnościom (uczucie mdłości) i wymiotom. Lek Emend stosuje się u pacjentów w wieku od 6 miesięcy celu zapobiegania nudnościom i wymiotom wywołanym chemioterapią (lekami stosowanymi w leczeniu raka).
What’s new. Find all new and updated information published on our website in one place below. Filters are available to narrow results down based on your interests, such as whether it relates to human or veterinary medicines or specific topics. This overview covers up to two months back. Current month Previous month Two months ago.
30 cze 2015 · The 1,000-patient trial revealed that a 150mg injection of neurokinin 1 antagonist Emend (fosaprepitant dimeglumine) was more effective than placebo – both given in combination with oral anti-vomiting drugs ondansetron and dexamethasone – in patients taking moderately-emetogenic chemotherapy (MEC).
2 wrz 2015 · Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has. approved a supplemental New Drug Application (sNDA) for EMEND ®. (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor. antagonist.
1 sie 2006 · Merck & Co.'s antiemetic Emend (aprepitant) has been granted expanded approval by the FDA to prevent postoperative nausea and vomiting (PONV). Emend, a substance P/neurokinin 1 (NK-1) receptor antagonist, works through a mechanism distinct from that of the 5-HT3 receptor antagonists.
EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning.
